What one share of Verastem holds
We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States (“U.S.”), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (“LGSOC”) who have received prior systemic therapy.
Verastem’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.03 |
|---|---|
| Profit | −$2.39 |
| Cash and investments | $1.51 |
| Book value | $0.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.14 | −$4.90 | $0.01 | −$3.69 | — | $5.67 |
| 2022 | $0.16 | −$4.57 | — | — | — | $2.84 |
| 2023 | — | −$3.96 | — | — | — | $2.27 |
| 2024 | $0.28 | −$3.66 | $0.00 | −$2.93 | — | −$0.65 |
| 2025 | $0.45 | −$3.02 | — | — | — | $0.74 |
Common questions about Verastem
How much does one share of Verastem earn?
Over the last 12 months, Verastem lost $2.39 for each share on $1.03 of sales.
Does Verastem pay a dividend?
Verastem didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Verastem’s book value per share?
Verastem’s book value is $0.55 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Verastem have?
Each share of Verastem has $1.51 of cash and investments, as of June 30, 2026.
Has Verastem bought back shares?
Verastem’s share count rose about 377% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.